US health officials are recommending easing restrictions on marijuana, a move that sets the stage for potentially expanding the cannabis market across the country. A top official at the Department of Health and Human Services wrote Drug Enforcement Agency Administrator Anne Milgram calling for marijuana to be reclassified as a Schedule III drug under the Controlled Substances Act, according to a letter dated Aug. 29 that was seen by Bloomberg News.
A DEA spokesperson confirmed the department had received the letter with HHS’s recommendation. With final authority to reschedule a drug, DEA will now initiate its own review, the spokesperson said.
Reclassification is a step short of legalizing the drug entirely, but it would mark a critical shift away from marijuana’s status as a Schedule I substance, which includes drugs with high risk of abuse, like heroin, LSD and ecstasy. Schedule III substances, such as ketamine, are seen as less dangerous and can be obtained legally with a prescription.
Huvitav kas mingi arutu õhin või kuskil miskit toimud?
Insider Trading
TLRY President and CEO Buy 53,700.00 1.88 SIMON IRWIN D 2024-01-12 TLYS 10% Owner Buy 50,400.00 1.31 Pleasant Lake Onshore Feeder Fund LP 2024-01-12 TLRY CFO Buy 20,000.00 1.87 Merton Carl A 2024-01-12 TLRY Global General Counsel Buy 5,400.00 1.87 Gendel M
TLRY häda on see, et nad pole kasumlikud. Juhul kui on soov patus püherdada siis Green Thumb Industries Inc. (GTBIF) on üks väheseid ettevõtteid mis suudab ka kasumit teenida. Oktoobri põhjadest on muidugi 30% juba rallitud ja täna veel lisa. Aga kui pakutakse 6.7 usd piirkonnast võtta siis ma arvan, et see on bueno.
Paljud valdkonna aktsiad tegid kevadel suure tõusu ja enamus neist jälle tagasi tõmbunud. Eile olevat WP-s olnud artikkel, mis võib tõsta paljude aktsiate hinnad jälle kõvasti ülespoole. Sel korral ehk saab näha ka tehnilistest tasemetest läbisurumist, mis omakorda toetaks tõusu.
Veebiavarustest leitud info on selline:
The surge in cannabis stocks on December 11, 2025, was primarily driven by a recent report that President Donald Trump is close to officially rescheduling marijuana from a Schedule I to a Schedule III controlled substance.
This news has fueled investor optimism, as rescheduling is expected to provide significant benefits to the industry by easing federal regulations, such as:
Tax Relief: It would allow cannabis companies to claim standard business tax deductions, which they are currently prohibited from doing under IRS Section 280E.
Access to Banking: Rescheduling would grant cannabis businesses better access to traditional banking services and financial institutions, rather than operating on a largely cash-only basis.
Increased Investment: Easing regulations could attract more institutional investment and potentially open the door to interstate commerce for U.S. companies.
Additionally, a new bill filed by a Florida state senator to legalize home cultivation of medical marijuana in that state has also contributed to positive sentiment, particularly benefiting companies with a strong presence in Florida, like Trulieve.
This recent optimism is part of a broader trend in late 2025, sparked by President Trump’s earlier public endorsements of cannabidiol (CBD) for senior healthcare and ongoing speculation regarding federal reform.